` IFRX (InflaRx NV) vs S&P 500 Comparison - Alpha Spread

IFRX
vs
S&P 500

Over the past 12 months, IFRX has underperformed S&P 500, delivering a return of -41% compared to the S&P 500's +13% growth.

Stocks Performance
IFRX vs S&P 500

Loading
IFRX
S&P 500
Add Stock

Performance Gap
IFRX vs S&P 500

Loading
IFRX
S&P 500
Difference
www.alphaspread.com

Performance By Year
IFRX vs S&P 500

Loading
IFRX
S&P 500
Add Stock

Competitors Performance
InflaRx NV vs Peers

S&P 500
IFRX
ABBV
AMGN
GILD
VRTX
Add Stock

InflaRx NV
Glance View

Market Cap
54.3m USD
Industry
Biotechnology

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

IFRX Intrinsic Value
0.6 USD
Overvaluation 30%
Intrinsic Value
Price
Back to Top